DADC
PETX

D.A. Davidson & Co’s Aratana Therapeutics, Inc. PETX Stock Holding History

D.A. Davidson & Co’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-240
Closed -$1K – 2558
2016
Q4 		$1K Sell
240
-2,804
-92% -$22.7K ﹤0.01% 2422
2016
Q3 		$28K Buy
+3,044
New +$25.3K ﹤0.01% 1754

Other funds holding PETX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

D.A. Davidson & Co's PETX Position: Q1 2017 in Review

D.A. Davidson & Co sold out of Aratana Therapeutics, Inc. (PETX) in Q1 2017, closing a stake of 240 shares — an estimated $1K sold.

D.A. Davidson & Co first reported a position in PETX in Q3 2016 and held it in 2 quarters. The position peaked at $28K in Q3 2016. 98 funds tracked by Wall St. Rank hold PETX as of Q1 2017.

  • D.A. Davidson & Co reported no remaining Aratana Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
  • D.A. Davidson & Co sold 240 Aratana Therapeutics, Inc. shares in Q1 2017, an estimated $1K.
  • D.A. Davidson & Co first reported a position in Aratana Therapeutics, Inc. in Q3 2016 and held it in 2 quarters.
  • D.A. Davidson & Co's Aratana Therapeutics, Inc. position peaked at $28K in Q3 2016.
  • 98 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q1 2017.

Based on D.A. Davidson & Co's 13F filing for Q1 2017, filed 12 May 2017.